Mayo Clinic And Virginia Tech Researchers Identify Five Distinct Subtypes Of Common Fatty Liver Disease

Researchers at the Mayo Clinic and Virginia Tech have identified five biologically distinct forms of metabolic dysfunction-associated steatotic liver disease, fundamentally shifting the medical understanding of a condition that affects nearly 30 per cent of adults worldwide. Rather than functioning as a single uniform pathology, the condition develops through multiple distinct biological pathways tied to obesity, diabetes, or inherited factors, carrying varying risks for heart disease, liver failure, and liver transplantation.

The findings, published in scientific literature, could enable clinicians to identify vulnerable patients much earlier and target treatments with greater precision. The discovery was enabled by advanced computational modelling applied to an extensive dataset combining genetic sequence data and detailed clinical records from more than 4,600 patients.

The research breakthrough relied heavily on large-scale computational analysis of patient populations. By examining liver enzyme levels, body mass index, blood lipid profiles, and concurrent conditions such as diabetes, depression, and sleep apnoea, investigators isolated specific groups sharing underlying biological signals. This methodological rigor allowed the team to map out five distinct subtypes with remarkable precision.

“When clinical and genomic data are analysed together at this scale, you begin to see patterns of disease progression that would otherwise remain hidden,” said Dr. Shulan Tian, co-senior author of the paper and a bioinformatician at Mayo Clinic. “Once you separate these subtypes, you can start to match treatments to the biology that’s actually driving the disease,” she noted, highlighting a shift toward personalized medicine.

The discovery was facilitated by Mayo Clinic’s Research Data Atlas, a computational platform linking genetic information with comprehensive clinical records across large patient cohorts. A cornerstone of this architecture is the Tapestry Study, which has amassed exome data from more than 100,000 participants to capture vital genetic variations influencing disease trajectories.

“This is exactly the kind of insight large-scale genomic research was built to deliver,” stated Dr. Konstantinos Lazaridis, the Carlson and Nelson Endowed executive director of the Center for Individualized Medicine at Mayo, who led the Tapestry Study and co-authored the research. “When you connect genetic data with detailed clinical information across large populations, you can start to redefine diseases in ways that directly impact patient care,” he added.

Beyond localized hepatic complications, the investigation uncovered novel systemic associations linked to specific disease subtypes. For the first time, researchers established connections between certain liver disease pathways and extra-hepatic conditions including depression, sleep apnoea, and migraine. These findings underscore the systemic nature of the pathology across multiple organ systems.

“What’s emerging here is a way to systematically identify meaningful subgroups within complex disease,” explained Dr. Eric Klee, co-senior author and the Everett J. and Jane M. Hauck Midwest associate director of research and innovation at Mayo Clinic. “It helps us map complex disease with such precision that we can begin to anticipate its course and intervene before the most serious damage occurs,” he said.

Looking toward future applications, the investigative team intends to test their classification methodology across broader patient populations. Researchers will also evaluate whether the newly identified subtypes respond differently to emerging pharmaceutical interventions, specifically glucagon-like peptide-1 receptor agonists.

As the medical community evaluates these genetic classifications, investigators emphasize that early identification remains the primary objective. By distinguishing hereditary drivers from metabolic risk factors, physicians aim to intercept advanced liver scarring, cirrhosis, and oncological developments before irreversible organ damage takes place.